IDEXX Jumps 8% Premarket: Pet Diagnostics Beat Powers a Guidance Raise

IDEXX Laboratories (NASDAQ: IDXX) jumped about 8% in premarket trading on Monday, November 2, 2026, after the pet healthcare company beat earnings and revenue estimates and raised its full-year 2026 guidance. The stock was quoted near $594 in premarket action, up from Friday's close of $551.21, making it one of the morning's biggest movers among large U.S. companies.

What happened

IDEXX reported third-quarter revenue of $1.214 billion, up 10% year over year on both a reported and an organic basis, beating the roughly $1.19 billion analysts expected. Diluted earnings per share were $4.01, up 18% as reported. On a comparable basis, EPS was $3.96, beating consensus by about $0.23 to $0.25 depending on the estimate set.

The engine was the Companion Animal Group. CAG revenue grew 10%, and CAG Diagnostics recurring revenue — the repeat testing and consumables business tied to IDEXX's installed base of analyzers — grew 11% to $967.4 million. Gross margin expanded 110 basis points to 62.9%, and operating margin rose 100 basis points to 33.1%.

The guidance raise, in full

IDEXX raised 2026 revenue guidance to $4,741 million–$4,767 million, up $32 million at the midpoint to $4,754 million. It also raised its 2026 EPS outlook to $14.96–$15.16, a $0.25 increase at the midpoint to $15.06. The company now expects reported revenue growth of 10.1%–10.8% for the year and organic revenue growth of 9.3%–10.0%, up from 8.5%–9.7% previously.

Management said the raise mainly reflects strong CAG Diagnostics recurring revenue, not one-off items. The new revenue range does include about $5 million linked to CoVet, the AI clinical assistant IDEXX acquired. IDEXX also placed more than 1,900 inVue Dx analyzers in the quarter, taking the installed base to nearly 11,000 — each placement tends to pull through future recurring testing revenue.

Why it's blowing up

First, this was a clean beat-and-raise on a morning when investors were hunting for good news. U.S. futures were rebounding from Friday's tech rout, and IDEXX stood out in premarket mover lists — Schwab Network put it up 4.68% in its early advancers list, and by 8:25 a.m. ET the premarket gain had widened to about 7.8%.

Second, the quality of the growth matters. Recurring diagnostics revenue growing faster than total revenue, at 11%, tells investors the installed base is being used more, not just sold into. That, plus double-digit revenue growth and expanding margins, is the combination that supported a guidance raise rather than a one-quarter beat that fades.

Third, there was one honest caveat in the release, and the market largely looked past it in early trading: IDEXX trimmed its full-year operating margin outlook to 32.1%–32.3%, down 20 basis points at both ends from 32.3%–32.5%, to reflect acquisition-related effects. Margin expansion for the year is now expected at 50 to 70 basis points instead of 70 to 90.

Key facts

Q3 revenue: $1.214 billion, up 10% reported and organic, versus about $1.19 billion expected.
Q3 EPS: $4.01 diluted as reported, up 18%; $3.96 on a comparable basis, beating consensus.
CAG Diagnostics recurring revenue: $967.4 million, up 11% reported and organic.
New 2026 guidance: revenue $4,741 million–$4,767 million; EPS $14.96–$15.16.
Premarket move: about +7.8% to near $594, versus a $551.21 Friday close. Premarket moves trade on thinner volume and can reverse after the open.

What's next

The next test is whether the premarket gain holds through the regular session and the company's earnings call discussion of veterinary visit trends, analyzer placements and the CoVet integration. Investors will also watch whether the lower margin range is a one-year acquisition effect, as IDEXX describes it, or the start of a slower margin path. This report is news coverage, not financial advice.

Sources

FAQ

Why did IDEXX stock jump on November 2, 2026?

IDEXX beat Q3 estimates on revenue and earnings and raised its full-year 2026 revenue and EPS guidance, sending the stock up about 8% in premarket trading.

What were IDEXX's Q3 2026 results?

Revenue was $1.214 billion, up 10% year over year, and diluted EPS was $4.01, up 18% as reported, with CAG Diagnostics recurring revenue up 11% to $967.4 million.

What is IDEXX's new 2026 guidance?

The company raised revenue guidance to $4,741 million–$4,767 million and its EPS outlook to $14.96–$15.16, while trimming its operating margin range to 32.1%–32.3% for acquisition-related effects.

What does IDEXX Laboratories do?

IDEXX is a pet healthcare company whose core business is diagnostics, analyzers, reference laboratory testing and software for companion animal veterinary practices.